FDA Advisory Panel Reviews Experimental Peptides for Compounding Pharmacies

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) met for two days to consider adding seven non-approved peptide substances to the 503A Bulks List, which would let state-licensed compounding pharmacies prepare them for patients with a valid prescription. The panel’s advice is non-binding; the FDA will make the final decision.

CNN

Peptides are short amino-acid chains; insulin and GLP-1 drugs such as Ozempic are approved examples. The seven peptides under review—BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax and Epitalon—are sold mainly through “research-use-only” channels and promoted for anti-aging, wound healing, obesity, opioid withdrawal, sleep and neurological conditions, despite lacking FDA approval.

CNN

• BPC-157 – ulcerative colitis

CNN

• KPV – wound-healing, anti-inflammatory

CNN

• TB-500 – wound-healing

CNN

• MOTs-C – obesity, osteoporosis

CNN

• Emideltide – opioid-withdrawal, insomnia, narcolepsy

CNN

• Semax – neurological disorders

CNN

• Epitalon – insomnia

CNN

• Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said a regulated compounding pathway could replace the unregulated online market but noted the lack of clinical-trial data.

CNN

• Jesse Dresser, partner at Frier Levitt, explained that placement on the list would create a lawful route for pharmacies to compound the ingredients with a physician’s prescription.

CNN

• Edgar Asebey, life-science attorney at the same firm, stressed that none of the peptides have completed FDA-approved Phase 1-3 trials, leaving safety and interaction profiles unknown.

CNN

• Dr. Janet Woodcock, retired FDA principal deputy commissioner, compared any future scheme to the dietary-supplement model, noting FDA can intervene only when products cause demonstrable harm.

CNN

If the FDA follows the committee’s advice, patients could obtain the peptides from licensed compounding pharmacies instead of unregulated internet vendors, potentially reducing exposure to adulterated products. Compounding pharmacies would gain a new revenue stream, and physicians might feel more comfortable prescribing under a regulated framework. However, legitimizing the peptides without solid safety data could expand their use and expose larger populations to uncertain risks.

CNN

All seven peptides lack Phase 1-3 clinical-trial data. Reviewers note that safety, toxicity and drug-interaction information remain largely speculative, and no quantitative efficacy metrics were presented.

CNN

• “The committee usually looks at research clinical trials, and if there’s supporting research clinical trial data, there’ll be a recommendation that they be added to a list of drugs that compounding pharmacies can prepare. That data just doesn’t exist for most of these peptides,” — Scott Brunner

CNN

• “Essentially, what that would do is it would create a lawful pathway for compounding pharmacies to be able to make products containing these ingredients and dispense them to patients,” — Jesse Dresser

CNN

• “We currently don’t know the long-term effects of many of these peptides; what are their toxicities, adverse effects or even their drug interactions. FDA approval – Phase 1, 2 and 3 clinical trials – require companies to perform extensive clinical studies to determine drug safety and efficacy. None of the peptides currently being considered for compounding are FDA approved drugs,” — Edgar Asebey

CNN

The PCAC will submit its advisory recommendations to the FDA. The agency will decide whether to amend the 503A Bulks List and possibly implement a “green list” of FDA-registered manufacturers for the peptide ingredients. Future guidance may follow the dietary-supplement model, allowing market access while retaining authority to act if adverse events arise.

CNN